Revolutionizing Early Autism Risk Detection
The sooner you know, the sooner you can help
Leverage the First-of-its-Kind Autism Risk Detection Test
Traditional autism diagnosis often takes years. But with NeuroQure's cutting-edge ASD Insight™ test, we're changing the game. Our autism risk test for children can detect markers as early as two days after birth, allowing for potential intervention sooner. Don't wait for behavioral signs to appear - empower your child's future today with early autism risk detection.
Transform Your Practice with Early Autism Risk Detection
As a physician, you play a crucial role in early autism risk detection. NeuroQure's ASD Insight™ autism risk screening test allows you to offer up to 80% accurate testing alongside traditional assessments. Provide families with earlier answers and pave the way for improved outcomes with autism risk testing.
Detecting Autism Earlier Creates the Best Chance For Successful Treatment
Since science has proven that autism is treatable through effective therapies*, the earlier treatment begins, the better the outcome for the child.
At NeuroQure, we're empowering people with children and physicians alike to transform lives. How? By receiving an accurate diagnosis of risk within days of a skin sample.
+17%
IQ Improvement
The Power of Early Autism Intervention
The Average Age of Diagnosis is 5 Years Old
41% in life-long services cost savings
Apply for qualifying services with traditionally long wait times
Plan ahead for living arrangements, schools, insurance, and more
Where Can You Get Testing For Autism Risk?
Right here at NeuroQure. Our ASD Insight™ children's autism risk test is non-invasive and provides impactful results. By detecting autism risk early, you open doors to a world of possibilities.
Early intervention autism programs can significantly improve language skills, social interactions, and cognitive development. Give your child or patients the best chance at thriving with our revolutionary early risk detection test.
Frequently Asked Questions
- General information: Autism spectrum disorder (ASD) has no defined biomarkers for diagnostics or novel drug discovery. A major cluster of ASD-associated loci encode calcium signaling proteins. Functional measurement of these signals in fibroblasts shows altered intracellular Ca2+ release in monogenic syndromes associated with ASD (FMR1, TSC1, TSC2, etc.), as well as sporadic ASD. Ca2+ channels in these patients demonstrate a reduced mean open-time and therefore low flux, while other measurable parameters, such as channel abundance, selectivity, conductance, and latency, are unchanged. This result is similar to single-channel kinetic changes seen in genetic Channelopathies.
- Methodology: The skin biopsy is processed using enzymatic dissociation and fibroblasts are cultured in standard medium. Cultured cells are plated in triplicate along with controls and then subjected to stimulation of Ca2+ signaling with ATP, ionomycin and buffer. All triplicates are averaged and normalized to a baseline based on triplicate controls included on each plate. The Ca2+ signal and closure of the calcium channel is calculated based on a previously published algorithm (Schmunk et al.) and reported as detected or not detected based on the rate of calcium flux on closure as compared to controls. The reference range is not detected based on the measured calcium flux, which is physiologic and in the range of that seen in neurotypical controls.
- References: Schmunk G, Nguyen RL, Ferguson DL, Kumar K, Parker I, Gargus JJ. High-throughput screen detects calcium signaling dysfunction in typical sporadic autism spectrum disorder. Sci Rep. 2017;7:40740 Nguyen RL, Medvedeva YV, Ayyagari TE, Schmunk G, Gargus JJ. Intracellular calcium dysregulation in autism spectrum disorder: An analysis of converging organelle signaling pathways. Biochim Biophys Acta Mol Cell Res. 2018;1865(11 Pt B):1718-1732.Schmunk G, Boubion BJ, Smith IF, Parker I, Gargus JJ. Shared functional defect in IP3R-mediated calcium signaling in diverse monogenic autism syndromes. Transl Psychiatry. 2015;5(9):e643.
- Disclaimer: The ASD Insight™ Test was developed and its performance characteristics were determined by Exceltox Laboratories, LLC 15375, Barranca Pkwy, E104 Irvine CA 92618. It has not been cleared or approved by the US Food and Drug Administration. This test is used for clinical purposes. It should not be regarded as investigational or for research. Exceltox Labs is accredited by the College of American Pathologists (CAP) under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing.
*Randomized, controlled trial for toddlers with autism demonstrated average IQ improvement of 17.6 standard points, underscoring the importance of early detection of and intervention in autism. [PubMed ID: 19948568]
Take the First Step Towards Early Risk Detection
Order your ASD Insight™ early autism risk detection test today.